In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, announce regulatory milestones, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).
Announced that OrthoPlanner™, a surgeon-designed digital tool that streamlines pre-operative fracture planning, received FDA clearance for all fracture anatomies. Accessible on smartphones and PCs, the platform enables faster, more precise trauma surgery with no additional hardware or setup required.
Received the Special Jury Prize at the EY Entrepreneur of the Year awards in recognition of its mission to bring trustworthy AI into radiology. Gleamer’s medical-grade AI solutions are designed to support diagnostic accuracy and workflow efficiency to improve care for millions of patients worldwide.
Raised $10M in an oversubscribed seed round to accelerate development of the SmartShunt™ Hydrocephalus Management System. The financing reflects strong investor confidence in Madison Scientific’s mission to bring innovation to a historically underserved and high-need market.
Welcomed LSI Alumni Joe Kiani, founder of Masimo, as an investor and board member to support the continued expansion of its Continuous Perfusion Sensing Technology (CPST) platform. Kiani’s leadership in patient monitoring aligns with MY01’s mission to transform trauma care and deliver earlier, data-driven diagnosis of limb perfusion injuries.
Expanded its Scientific Advisory Board with the addition of three leading thoracic surgeons, Drs. Brian Burt, Brian Mitzman, and Jeffrey Velotta, to support early clinical adoption of the NaviSci™ System. Their expertise will guide clinical workflow design, user interface development, and site selection for initial trials.
Appointed Jerome Descheirder as Global Chief Commercial Officer to lead global sales and commercial strategy, while Stefan Bircher transitions into the new role of Chief Business Development and Marketing Officer. The expanded leadership team will support Positrigo’s accelerating growth and broaden market adoption of its NeuroLF PET brain imaging system.
Received FDA Investigational Device Exemption (IDE) approval to initiate the NANOCLAMP AF study evaluating its nsPFA Cardiac Surgical System for the treatment of atrial fibrillation. The single-arm, prospective study will enroll up to 136 patients across up to 20 sites and marks a major milestone for advancing nonthermal ablation in surgical cardiac care.
Closed a $67M Series D round led by JJDC and signed a targeted collaboration agreement with Johnson & Johnson Medical (Shanghai) to expand surgical technology choice and access in China. With over $100M raised in 2025 alone, Ronovo is accelerating commercialization and has initiated global expansion.
Submitted its NeuroHawk™ system to the FDA for clearance as a rapid, non-invasive diagnostic platform for stroke and traumatic brain injury. Designed for use at the point of care, including ambulances and ICUs, NeuroHawk delivers real-time brain bleed detection in under four minutes, aiming to transform emergency neurocritical care.
Reported positive interim data from ongoing clinical trials of REGENERA™/SOFTAG™, its bioresorbable scaffolds for breast reconstruction and tissue marking. The device met primary safety and secondary performance objectives, showed high patient and surgeon satisfaction, and supports both aesthetic restoration and radiotherapy planning ahead of anticipated regulatory approvals in 2027.
Announced that it has been acquired by Edwards Lifesciences at a $497M valuation. The deal was executed in two stages, with Edwards acquiring 52% of Vectorious in 2023 and the remaining 48% in 2025.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy